Prosecution Insights
Last updated: November 20, 2026
Application No. 18/277,969

METHODS AND COMPOSITIONS TO CONFER REGULATION TO GENE THERAPY CARGOES BY HETEROLOGOUS USE OF ALTERNATIVE SPLICING CASSETTES

Final Rejection §112§DOUBLEPATENT
Filed
Aug 18, 2023
Priority
Feb 19, 2021 — provisional 63/151,402 +1 more
Examiner
ZARA, JANE J
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Florida Research Foundation Inc.
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
788 granted / 1109 resolved
+11.1% vs TC avg
Strong +16% interview lift
Without
With
+16.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
49 currently pending
Career history
1160
Total Applications
across all art units

Statute-Specific Performance

§101
5.4%
-34.6% vs TC avg
§103
30.6%
-9.4% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
33.1%
-6.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1109 resolved cases

Office Action

§112 §DOUBLEPATENT
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This Office action is in response to the communication filed 9-18-26. Claims 1, 3-5, 30, 32, 35, 37, 40-42, 44, 50, 57, 59, 63, 64, 80, and 81 are pending in the instant application. Claims 57, 59, 63, 64, 80, and 81 are withdrawn as being drawn to a nonelected invention or species. Claims 1, 3-5, 30, 32, 35, 37, 40-42, 44 and 50 have been examined on their merits as set forth below. Withdrawn Rejections Any rejections not repeated in this Office action are hereby withdrawn. New Rejections Necessitated by Amendments Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 3-5, 30, 32, 35, 37, 40-42, 44 and 50 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. The breadth of the claims: The claims are drawn to transgenes comprising:(i) a constitutive exon and one or more intronic sequences, each from a first gene optionally comprising survival motor neuron 1 (SMN1); (ii) an alternatively-spliced exon cassette comprising a) an alternatively-spliced exon, and (b) flanking intronic sequences, wherein each of (a) and (b) are from a second gene optionally comprising calcium/calmodulin- dependent protein kinase II beta (CAMK2BI,plakophilin 2 (PKP21,legumain (LGMN, nebulin-related anchoring protein (NRAP),VPS39 subunit of HOPS complex (VPS391, kinase suppressor of Ras 1 (KSR1,PDZ and LIM domain protein 3 tPDLIM31, bridging integrator 1 (BIN1Q,ARF GTPase-activating protein 2 (ARFGAP21,kinase family member 13A (KIF13A, and phosphatidylinositol binding clathrin assembly protein (PICALM), and (iii) a coding region of interest from a third gene optionally comprising myotubularin 1 (MTM1) or calpain 3, which first, second and third genes are different genes, which alternatively-spliced exon comprises an ATG start codon, which constitutive exon of (i) comprises exon 6 of SMN1, or a portion thereof; the one or more intronic sequences of (i) are or are derived from intron 6 and/or intron 7 of SMN1; the alternatively-spliced exon of (ii) comprises exon 11 of BIN1; or the flanking intronic sequences of (ii) are or are derived from intron 10 and/or intron 11 of BIN1, which constitutive exon of (i)comprises a polynucleotide having at least 70%, at least 75%, at least 80%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity relative to SEQ ID NO: 102; the one or more intronic sequences of (i) comprise(s) a polynucleotide having at least 70%, at least 75%, at least 80%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 103 and/or SEQ ID NO: 104, the alternatively-spliced exon of (ii) comprises a polynucleotide having at least 70%, at least 75%, at least 80%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity to either SEQ ID NO: 37 or SEQ ID NO: 38;the flanking intronic sequences of (ii) each comprise a polynucleotide having at least 70%, at least 75%, at least 80%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity with either SEQ ID NO: 15 or SEQ ID NO: 16; the alternatively-spliced exon cassette of (ii) comprises a polynucleotide having at least 70%, at least 75%, at least 80%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence SEQ ID NO: 729; or the coding region of interest of (iii) comprises a polynucleotide having at least 70%, at least 75%, at least 80%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 1881 or SEQ ID NO: 1882, which constitutive exon of (i)is located 5’ relative to the alternatively-spliced exon cassette of (ii): the one or more intronic sequences of (i) flank the alternatively-spliced exon cassette of(ii): the alternatively-spliced exon cassette of (ii) is located 5' relative to the coding region of interest of (iii): the ATG start codon in the alternatively spliced exon of (ii) is in the same reading frame as the coding region of interest of (iii): the ATG start codon in the alternatively spliced exon of (ii) is within up to 5, 10, 20, or 30 nucleotides upstream of the 3' end of the alternative-spliced exon, which alternatively-spliced exon of (ii comprises a heterologous, in-frame stop codon, optionally wherein the heterologous, in-frame stop codon is at least 50 nucleotides upstream of the next 5' splice junction or elicits nonsense- mediated decay, which alternatively-spliced exon of (ii is retained in the spliced transcript in distinct tissues, which flanking intronic sequences of (ii)(b) are or are derived from native flanking introns of the alternatively-spliced exon or each comprise at least one modification relative to a naturally occurring intronic sequence, and which ATG start codon is located at the 3' end of the alternatively-spliced exon of (ii), or optionally which wild-type alternatively- spliced exon does not comprise an ATG start codon at its 3' end and the first 10 nucleotides of the flanking intronic sequence which is immediately 3' to the alternatively-spliced exon of (ii) comprise 1-5 nucleotide substitutions relative to the wild-type flanking intronic sequence which is immediately 3' to the wild-type alternatively-spliced exon, wherein the one or more intronic sequences of (i) each comprise at least one modifications relative to a naturally occurring intronic sequence, optionally wherein the modification is a substitution or deletion of one or more nucleic acids, which coding region of interest of (iii) comprises at least one modification relative to a naturally occurring coding region of the third gene, optionally wherein the modification is a substitution or deletion of one or more nucleic acids; the coding region of interest comprises a deletion or disruption of a native start codon; or the coding region of interest comprises at least one heterologous stop codon, further optionally wherein the at least one heterologous stop codon is at least 50 nucleotides upstream of the next 5' splice junction or the at least one heterologous stop codon elicits nonsense-mediated decay, and optionally further comprising a 3' untranslated region (UTR) or a promoter located 5' relative to all of (i), (ii), and (iii), optionally wherein the 3' UTR comprises a polyadenylation (pA) site and a cleavage site and the promoter is a tissue-specific promoter, further optionally wherein the tissue-specific promoter is an MHCK7 promoter. Teachings in the specification The specification teaches the intention of screening candidate exons compiled from heart and skeletal muscle RNAseq data (see text on page 151; Table 1 on pages 152-156). The exons shown in Table 1 will be tested to evaluate differential expression in skeletal versus heart tissue. These exons are good candidates for this type of tissue-specific behavior because they show robust switch-like behavior between heart and muscle. Some of the exons shown in Table 1 are conserved between mouse and human, and, correspondingly, the switch-like behavior is conserved across species. In some embodiments, the intronic sequences that flank the exons shown in Table 1 are also included as part of the regulatory cassette. These exons were chosen because of their switch-like behavior between heart and muscle, and because they are all < 250 nucleotides in length, with reasonably conserved intronic sequences that flank the exons. Additionally, these exons are all amenable to being cloned out of their endogenous context and placed into a minigene to act as regulatory cassettes to control AAV cargo expression. It is expected that incorporation of these exons into an AAV-delivered transgene will enable production of a protein cargo in the skeletal muscle and will result in decreased production of that cargo in the heart. The specification also describes the intention of testing exons from genes that have been previously shown to exhibit splicing changes upon T-cell activation and listed in Table 2 on page 157. In some embodiments, the intronic sequences flanking the exons shown in Table 2, along with the exons, will be introduced into a lentivirus splicing reporter and tested in resting and activated T-cells to assess activity. Sequence cassettes that exhibit behavior that is similar to their endogenous counterparts will be further developed to control heterologous cargoes. Exons from these genes were selected because they have been observed to change in splicing behavior following T-cell activation. It is expected that, when taken out of their endogenous context and placed within an AAV-delivered transgene, some of the exons will recapitulate behavior in activated T-cells. On page 160, more datasets are listed for future identification of tissue specific exons: Examples of datasets used to identify tissue specific exons can be found in Wang, et al.(2008), Alternative isoform regulation in human tissue transcriptomes, Nature 456(7221): 470- 76; Li, et al. (2017), A Comprehensive Mouse Transcriptomic BodyMap across 17 Tissues by RNA-seq, Sci. Rep. 7(1): 4200; and the GEO dataset entitled "[E-MTAB-513] Illumina Human Body Map 2.0 Project" (Series GSE30611). Example 5: Research operating procedure. A general research operating procedure for how to develop gene therapies that take advantage of alternative regulation is also provided. This approach can be generalized to facilitate the identification of particular sequences that confer regulatory behavior that is desired. RNAscq datasets were analyzed to identify candidate exons that display extreme "switch-like" behavior between human heart (10) and skeletal muscle (SRA project SRP082676). These candidates were further filtered by those that were also conserved to mouse, and those which displayed similar percent spliced in (psi) values in mouse heart (low psi) and skeletal muscle (high psi). A set of 11 cassette exons were selected and ~500 nucleotides of total sequence were cloned-including the cassette exon and immediately adjacent flanking introns-into the SMN1 exon 6/intron 7 context, which has been previously used to study alternative splicing regulation (11) (FIG. 10). The MTM1 coding sequence, which expresses the myotubularin protein, a protein that is missing in boys affected by X-linked myotubular myopathy (12) (XLMTM), was chosen as the therapeutic cargo. Although MTM1 expression in skeletal muscle is therapeutic, questions have been raised about whether over-expression in heart can lead to toxicity… (Page 163). Mutations to facilitate translation initiation at the end of the alternative exon and avoid spurious downstream translation For each of the alternative exon candidates, the final nucleotides of the exon were altered to cither be "ATG", "AT", or "A" (depending on which nucleotides naturally occurred), such that initiation of translation could be achieved when the exon was included. Additionally, any upstream ATGs within the alternative exon were removed by substitution or deletion, to avoid translation initiation at an earlier location. In the case of exon skipping, downstream ATGs within the MTM1 coding sequence might lead to translation of unwanted protein fragments; thus, stop codons were introduced within 15 nucleotides of each of these ATGs, such that translation would terminate within just a few (<5) amino acids (FIG. 11). These ATGs and stop codons all resided in a reading frame distinct from the normal MTM1 reading frame, and thus mutations required to generate these stop codons could preserve the amino acid composition of MTM1. For other cargoes in which internal methionines are present, new out-of-frame short peptide sequences could be introduced upstream of these methionines such that translation of these short, benign peptides is favored over translation of a N-terminally truncated cargo (re-initiation of translation following a stop codon typically does not occur unless there are additional regulatory elements such as internal ribosomal entry sites). (page 164). The specification also teaches mutagenesis to preserve splice site strength and to address considerations of the Kozak sequence on page 165: Because changes to the end of the alternative exon sequence can affect the strength of the alternative exon's 5' splice site, both the original and altered 5' splice sites of the alternative exon were scored using MaxEntScan (14) and compensatory mutations were made to the intronic bases of the alternative exon's 5' splice site to compensate for any potential weakening of the splice site signal (FIG. 12; Table 3). The bases of the alternative exon which upstream of the ATG initiation sequence were also analyzed for translation initiation potential (15), and almost all sequences in this set showed reasonably strong scores. Additional mutations within the alternative exon could be made to increase similarity to the Kozak consensus sequence. All 11 alternative exon candidates (see Table 3 for exon coordinates, psi values, translational initiation scores, and sequence alterations) were packaged into AAV9 as a pool and administered to mice systemically (retro-orbital injection, 4 C57/BL6 mice and 2 FVB mice at 6 weeks of age, 2e13 vg/kg) and intramuscularly (4 C57/BL6 mice at 6 weeks of age, tibialis anterior, 2e11 vg total into one leg). Mice were sacrificed after 4 weeks; the heart and liver were harvested from the systemically injected animals and the tibialis anterior (TA) was harvested from the intramuscularly injected animals. On page 167, an analysis of deep sequencing reads is provided: Psi values were computed by associating junction reads to barcodes and computing the frequency of inclusion versus exclusion of each exon (FIGs. 14A-14C). Exons from BIN1, CAMK2B, KIF13A, LGMN, and PICALM showed higher inclusion levels in skeletal muscle (TA) and heart (H), and the BIN1 exon candidate showed the largest dynamic range, with ~ ~15% inclusion in heart and ~60% in TA. In addition, the BIN1 exon also showed ~0% inclusion in liver (L). These results provide proof of concept for the overall screening strategy and identify alternative exon cassettes that would be predicted to minimize translation of MTM1 in heart as compared to skeletal muscle. On page 168, the specification lists additional variables affecting alternative splicing that need to be addressed in generating recombinant constructs useful for alternative splicing: Based upon the initial hits of the first screen, described above, alternative exon cassette sequences were identified which might further enhance the switch-like behavior in heart versus skeletal muscle. A higher throughput approach was taken to simultaneously screen many sequence variants of candidate alternative exon cassettes. Core splice site sequences as well as intronic/exonic sequences play important roles in splicing decisions, by modulating the ability of specific trans-factors to bind a pre-mRNA. The core splicing signals, which include the 3' splice site, 5' splice site, and branch point, can all influence the frequency with which an alternatively spliced exon is chosen. These core splicing signals are recognized by the U1, U5, and U2 snRNPs, among other components; but they may also be bound by other RNA binding proteins (RBPs), which play roles in modulating how well the basal splicing machinery can recognize the core signals. Furthermore, RBPs can bind to intronic or exonic sequence in the vicinity of these core splicing signals to affect overall splicing decisions. The abundance of certain RBPs in certain contexts can therefore influence splicing patterns in those contexts. To aid efforts to further optimize sequences that display switch-like alternative splicing in heart versus skeletal muscle, the expression level of RNA binding proteins in these 2 tissues was analyzed (FIGs. 16A-16B). RNA expression levels were obtained from GTEX (17), and RBPs were defined from RBPDB (18). The ratio of expression in heart versus skeletal muscle was computed, and used to identify RBPs showing strongest differential expression between these 2 tissues; these RBPs would be predicted to be trans-factors that might be responsible for influencing splicing decisions of highly heart versus skeletal muscle-specific exons. The high throughput screening approach described herein was first applied to BIN1 exon 11 because it showed the largest dynamic range in psi between heart and skeletal muscle (see FIGs. 14A-14C). BIN1 exon 11 has been previously studied and demonstrated to be responsive to RNA binding proteins such as the Muscleblind-like proteins (19) and RBFOX proteins (20); consistent with this, RBFOX1 and MBNL1 are the 5th- and 11th-most enriched RBPs, respectively, in skeletal muscle relative to heart. The upstream intron of BIN1 exon 11 is enriched for CAC motifs (10 instances versus an expectation of 3.8); pairs of CAC motifs separated by a variable spacer are known to bind RBPMS2 (21). RBPMS2 represses exon inclusion when binding to upstream introns (22) and is the 2nd-most enriched RBP in heart as compared to skeletal muscle. Notably, the psi values of BIN1 exon 11 in human and rhesus macaque heart are all close to 0%, but in dog, which contains only 1 instead of 2 CAC motifs in the 3' splice site of BIN1 exon 11, unlike the other organisms, shows a psi value of ~50% for BIN1 exon 11 (23) (FIGs. 17 and 18). Thus, RBPMS2 might be a critical factor that represses BIN1 exon 11 in heart. On page 169, the specification describes the generation of AAV plasmid libraries for screening for possible splice sites, intronic sequences, CAC motifs, MBNL and RBFOX binding sites. Given all of the above information, the 3' splice site, 5' splice site (FIG. 19), and downstream intron (FIG. 20) of BIN1 exon 11 was systematically altered to explore different splice site strengths, different configurations of CAC motifs within the 3' splice site, and MBNL and RBFOX binding sites within the downstream intron: different frequencies of MBNL and RBFOX binding sites within the downstream intron. In total, AAV plasmid libraries were generated that contained 7 possible 3' splice sites, 6 possible 5' splice sites, and 16 possible downstream intronic sequences. The splice sites varied in strength, and the intronic sequences varied in the number of predicted MBNL and RBFOX binding sites. A total of 672 sequence variants were possible; each variant was linked to unique 10 nucleotide- long barcodes placed within the downstream coding sequence of MTM1. Each variant could be linked to several unique barcodes, such that multiple barcodes could serve as "replicates" for each sequence variant. Deep sequencing of PCR products amplified from plasmid libraries (FIG. 21) showed the presence of 663/672 variants, with an average of ~8 barcodes per variant (FIG. 22). Viruses were generated using the eMyoAAV capsid (24) and administered to mice at a titer of 2.5e13 vg/kg. Heart, tibialis anterior, and triceps muscles were collected from mice sacrificed 3 weeks following administration. Sequencing libraries were prepared by RT-PCR and sequenced by Illumina sequencing. Psi values were computed for each barcode and a psi value for each variant was obtained by averaging the psi across every barcode for each variant. The psi value for each variant is shown for 2 heart samples in a scatter plot (FIG. 23A), and similarly, for 2 gastrocnemius samples (FIG. 23B), or a heart sample versus a gastrocnemius sample (FIG. 23C). The mean psi was computed for each variant across replicate tissues from multiple animals (n=4 animals for each tissue). These mean psi values for each variant were also plotted (FIGs. 24A-24B) and listed (Table 4). Psi values for each variant were also plotted as a function of 3' splice site strength or 5' splice site strength in heart and gastrocnemius (FIGs. 25A-25D), and clear dependencies of psi on splice site strength were observed. This relationship is particularly strong between 5' splice strength and psi, supporting the idea that this screening approach can accurately quantitate relative psi values and identify sequence variants that exhibit specific splicing patterns. The same BIN1 exon 11 variants were also tested with a different cargo, CAPN3. A separate AAV library was generated in which all 672 BIN1 variants (Table 4) were cloned upstream of the CAPN3 coding sequence, analogously to how they were cloned upstream of the MTM1 coding sequence. Similarly, a 10 nucleotide barcode was embedded within the CAPN3 coding sequence to identify each splice variant. The mean psi values across heart, gastrocnemius, and tibialis anterior tissues from 4 animals were plotted as scatters (FIGs. 26A-26B), showing that some variants show lower inclusion in heart than in skeletal muscles. The overall behavior of each variant is strongly correlated across MTM1 and CAPN3 cargoes, but the baseline inclusion level of the BIN1 cassette is lower when linked to the CAPN3 cargo; this trend is observable when plotting the scatter of psi variants for each cargo in heart and gastrocnemius (FIGs. 27A-27B). [Emphases added] [Citations omitted]. The specification fails to provide the requisite guidance to adequately describe the broad genus of nucleic acid constructs instantly claimed. The examples, including the screening of libraries in the future, and prophesies of results of future experiments, fail to provide a representative number of species adequately describing the expansive genus of transgenes claimed. Since the disclosure fails to describe the common attributes and characteristics concisely identifying members of the proposed genus, and because the claimed genus is highly variant, the description provided is insufficient. One of skill in the art would reasonably conclude that the disclosure fails to provide a concise description of the broad genus of nucleic acid constructs, transgenes, and their subcomponents instantly claimed. Thus, Applicant was not in possession of the broadly claimed genus. Maintained Rejections Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 30, 32, 35, 37, 40-42, 44 BS 50 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of copending Application No. 19/105,597 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims recite transgenes comprising constitutive exons, intronic sequences, alternatively spliced exon cassettes and coding regions of interest. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Applicant’s Arguments No arguments were made addressing this rejection. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Certain papers related to this application may be submitted to Art Unit 1637 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. ' 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (571) 272-0765. The examiner’s office hours are generally Monday-Friday, 10:30am - 7pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jennifer Dunston, can be reached on (571)-272-2916. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Jane Zara 11-10-26 /JANE J ZARA/Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Aug 18, 2023
Application Filed
Jun 18, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT
Sep 18, 2026
Response Filed
Nov 13, 2026
Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799147
RIBONUCLEIC ACID PURIFICATION
3y 6m to grant Granted Nov 17, 2026
Patent 12774468
DEFINED MULTI-CONJUGATES OLIGONUCLEOTIDES
3y 1m to grant Granted Oct 27, 2026
Patent 12735704
ANTICANCER ADJUVANT AND PHARMACEUTICAL COMPOSITION FOR TREATING ANTICANCER-AGENT-RESISTANT CANCER, AND KIT COMPRISING SAME
3y 11m to grant Granted Sep 15, 2026
Patent 12734251
COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
3y 7m to grant Granted Sep 15, 2026
Patent 12703734
METHOD OF ASSESSING ACTIVITY OF RECOMBINANT ANTIGEN RECEPTORS
2y 9m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
87%
With Interview (+16.1%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1109 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month